Evidence map›Paper›PMID 34695998›Full record

ArticleSensors (Basel, Switzerland)2021

Automated ELISA On-Chip for the Detection of Anti-SARS-CoV-2 Antibodies.

Everardo González-González, Ricardo Garcia-Ramirez, Gladys Guadalupe Díaz-Armas, Miguel Esparza, Carlos Aguilar-Avelar, Elda A Flores-Contreras, Irám Pablo Rodríguez-Sánchez, Jesus Rolando Delgado-Balderas, Brenda Soto-García, Diana Aráiz-Hernández and 5 more

Open access · goldAbstract read
In one paragraph

Article in Sensors (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. High-throughput and automated screening for COVID-19.Frontiers in medical technology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Everardo González-GonzálezDelee Corp., Mountain View, CA 94041, USA.
Ricardo Garcia-RamirezDelee Corp., Mountain View, CA 94041, USA.
Gladys Guadalupe Díaz-ArmasDelee Corp., Mountain View, CA 94041, USA.ORCID 0000-0003-3235-8106
Miguel EsparzaDelee Corp., Mountain View, CA 94041, USA.ORCID 0000-0001-9678-8258
Carlos Aguilar-AvelarDelee Corp., Mountain View, CA 94041, USA.ORCID 0000-0001-5516-7391
Elda A Flores-ContrerasDepartamento de Bioquímica y Medicina Molecular, Facultad de Medicina, Universidad Autónoma de Nuevo León, San Nicolás de los Garza 64460, NL, Mexico.
Irám Pablo Rodríguez-SánchezLaboratorio de Fisiología Molecular y Estructural, Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León, San Nicolás de los Garza 66455, NL, Mexico.
Jesus Rolando Delgado-BalderasDelee Corp., Mountain View, CA 94041, USA.ORCID 0000-0002-9016-2016
Brenda Soto-GarcíaDelee Corp., Mountain View, CA 94041, USA.
Diana Aráiz-HernándezDelee Corp., Mountain View, CA 94041, USA.
Marisol Abarca-BlancoDelee Corp., Mountain View, CA 94041, USA.
José R Yee-de LeónDelee Corp., Mountain View, CA 94041, USA.
Liza P Velarde-CalvilloDelee Corp., Mountain View, CA 94041, USA.
Alejandro Abarca-BlancoDelee Corp., Mountain View, CA 94041, USA.
Juan F Yee-de LeónDelee Corp., Mountain View, CA 94041, USA.
Universidad Autónoma de Nuevo León · MXTecnológico de Monterrey · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The COVID-19 pandemic has been the most critical public health issue in modern history due to its highly infectious and deathly potential, and the limited access to massive, low-cost, and reliable testing has significantly worsened the crisis. The recovery and the vaccination of millions of people against COVID-19 have made serological tests highly relevant to identify the presence and levels of SARS-CoV-2 antibodies. Due to its advantages, microfluidic-based technologies represent an attractive alternative to the conventional testing methodologies used for these purposes. In this work, we described the development of an automated ELISA on-chip capable of detecting anti-SARS-CoV-2 antibodies in serum samples from COVID-19 patients and vaccinated individuals. The colorimetric reactions were analyzed with a microplate reader. No statistically significant differences were observed when comparing the results of our automated ELISA on-chip against the ones obtained from a traditional ELISA on a microplate. Moreover, we demonstrated that it is possible to carry out the analysis of the colorimetric reaction by performing basic image analysis of photos taken with a smartphone, which constitutes a useful alternative when lacking specialized equipment or a laboratory setting. Our automated ELISA on-chip has the potential to be used in a clinical setting and mitigates some of the burden caused by testing deficiencies.

Indexed as

COVID-19SARS-CoV-2Antibodies, ViralEnzyme-Linked Immunosorbent AssayHumansPandemicsSensitivity and SpecificityAntibodies, ViralantibodiesautomatedCOVID-19ELISAmicrofluidicson-chipSARS-CoV-2serologyspike protein

Identifiers

PMID34695998
PMCPMC8539637
OpenAlexW3205336588

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.